Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report
Open accessAbstract
Clinical trials evaluating medicines, medical devices, and procedures now commonly assess the economic value of these interventions. The growing number of prospective clinical/economic trials reflects both widespread interest in economic information for new technologies and the regulatory and reimbursement requirements of many countries that now consider evidence of economic value along with clinical efficacy. As decision makers increasingly demand evidence of economic value for health care interventions, conducting high-quality economic analyses alongside clinical studies is desirable because they broaden the scope of information available on a particular intervention, and can efficiently provide timely information with high internal and, when designed and analyzed properly, reasonable external validity. In 2005, ISPOR published the Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force report. ISPOR initiated an update of the report in 2014 to include the methodological developments over the last 9 years. This report provides updated recommendations reflecting advances in several areas related to trial design, selecting data elements, database design and management, analysis, and reporting of results. Task force members note that trials should be designed to evaluate effectiveness (rather than efficacy) when possible, should include clinical outcome measures, and should obtain health resource use and health state utilities directly from study subjects. Collection of economic data should be fully integrated into the study. An incremental analysis should be conducted with an intention-to-treat approach, complemented by relevant subgroup analyses. Uncertainty should be characterized. Articles should adhere to established standards for reporting results of cost-effectiveness analyses. Economic studies alongside trials are complementary to other evaluations (e.g., modeling studies) as information for decision makers who consider evidence of economic value along with clinical efficacy when making resource allocation decisions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The economic evaluation will be performed from a societal perspective, and all analyses will be conducted according to the intention-to-treat principle, adhering to the related guidelines.
“The economic evaluation will be performed from a societal perspective, and all analyses will be conducted according to the intention-to-treat principle, in which we adhere to the related guidelines [67–69].”
Parameter uncertainty will be covered by sensitivity analyses in which imputed uncertainty is also taken into account by repeating the economic evaluation on the imputed dataset, and sampling uncertainty will be taken into account by providing a cost-effectiveness acceptability curve and frontier.
“For example, parameter uncertainty will be covered by, for example, sensitivity analyses in which imputed uncertainty is also taken into account by repeating the economic evaluation on the imputed dataset and sampling uncertainty will be taken into account by providing a cost-effectiveness acceptability curve and frontier [67].”
Best practice within-trial economic evaluation methods will be adopted.
“Best practice within-trial economic evaluation methods will be adopted53”
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500 · see citing works
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701 · see citing works
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,384 · see citing works
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648 · see citing works
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371 · see citing works
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · see citing works
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193 · see citing works
Awais, A. (2015) · Data Archiving and Networked Services (DANS) · doi:10.17632/zcvgc6m58h.1 · Cited by 6,790 · see citing works
Statistical Analysis With Missing Data
Ghosh, S., Little, R. J. A., & Rubin, D. B. (1988) · Technometrics · doi:10.2307/1269814 · Cited by 4,730 · see citing works
(1997) · doi:10.1097/00005650-199711000-00002 · Cited by 4,544 · see citing works
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949 · see citing works
CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials
Schulz, K. F., Altman, D. G., Moher, D., & for the CONSORT Group* (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00232 · Cited by 3,824 · see citing works
The estimation of a preference-based measure of health from the SF-36.
Brazier, J., Roberts, J., & Deverill, M. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00130-8 · Cited by 3,164 · see citing works
The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument
Reilly, M. C., Zbrozek, A. S., & Dukes, E. M. (1993) · PharmacoEconomics · doi:10.2165/00019053-199304050-00006 · Cited by 3,071 · see citing works
Quality of life and pharmacoeconomics in clinical trials
Pater, J. L. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)82191-5 · Cited by 2,412 · see citing works
Multiple Imputation for Nonresponse in Surveys.
Lynn, P. J., & Rubin, D. B. (1988) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.2307/2348774 · Cited by 2,330 · see citing works
Confidence intervals rather than P values: estimation rather than hypothesis testing.
Gardner, M. J., & Altman, D. G. (1986) · BMJ · doi:10.1136/bmj.292.6522.746 · Cited by 2,014 · see citing works
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998 · see citing works
Self-citationSmithson, M. J. (2000) · SAGE Publications Ltd eBooks · doi:10.4135/9781446218525 · Cited by 1,871 · see citing works
Mode of questionnaire administration can have serious effects on data quality
Bowling, A. (2005) · Journal of Public Health · doi:10.1093/pubmed/fdi031 · Cited by 1,870 · see citing works
Quality of life and pharmacoeconomics in clinical trials
Spilker, B. (1996) · DigitalGeorgetown (Georgetown University Library) · Cited by 1,858 · see citing works
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834 · see citing works
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827 · see citing works
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., Loder, E., et al. (2013) · BMJ · doi:10.1136/bmj.f1049 · Cited by 1,776 · see citing works
Self-citationJanssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., Swinburn, P., & Busschbach, J. (2013) · Quality of Life Research · doi:10.1007/s11136-012-0322-4 · Cited by 1,582 · see citing works
Cost-Effectiveness in Health and Medicine
(2016) · doi:10.1093/acprof:oso/9780190492939.001.0001 · Cited by 1,552 · see citing works
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 System
Feeny, D. F., Furlong, W. J., Torrance, G. W., Goldsmith, C. H., Zhu, Z., Depauw, S., Denton, M. A., & Boyle, M. (2002) · Medical Care · doi:10.1097/00005650-200202000-00006 · Cited by 1,333 · see citing works
Explanatory and Pragmatic Attitudes in Therapeutical Trials
Schwartz, D., & Lellouch, J. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.01.012 · Cited by 1,253 · see citing works
An Introduction to the Bootstrap.
Kimber, A., Efron, B., & Tibshirani, R. J. (1994) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.2307/2348146 · Cited by 1,246 · see citing works
Explanatory and pragmatic attitudes in therapeutical trials
Schwartz, D., & Lellouch, J. (1967) · Journal of Chronic Diseases · doi:10.1016/0021-9681(67)90041-0 · Cited by 1,185 · see citing works
Some Problems in Interval Estimation
Fieller, E. C. (1954) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1954.tb00159.x · Cited by 1,159 · see citing works
Recommendations for Reporting Cost-effectiveness Analyses
Siegel, J. E. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540160061034 · Cited by 1,147 · see citing works
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,145 · see citing works
Representing uncertainty: the role of cost‐effectiveness acceptability curves
Fenwick, E. A. L., Claxton, K., & Sculpher, M. J. (2001) · Health Economics · doi:10.1002/hec.635 · Cited by 1,112 · see citing works
Stinnett, A. A., & Mullahy, J. (1998) · Medical Decision Making · doi:10.1177/0272989x98018002s09 · Cited by 1,103 · see citing works
Siegel, J. E. (1996) · JAMA · doi:10.1001/jama.276.16.1339 · Cited by 1,040 · see citing works
Manca, A., Hawkins, N., & Sculpher, M. J. (2005) · Health Economics · doi:10.1002/hec.944 · Cited by 1,024 · see citing works
Caro, J., Briggs, A., Siebert, U., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.012 · Cited by 1,006 · see citing works
Self-citationThe Work Limitations Questionnaire
Lerner, D., Amick, B. C., Rogers, W. H., Malspeis, S., Bungay, K. M., & Cynn, D. J. (2001) · Medical Care · doi:10.1097/00005650-200101000-00009 · Cited by 977 · see citing works
Costs, effects and C/E‐ratios alongside a clinical trial
van Hout, B. A., Al, M., Gordon, G. S., & Rutten, F. (1994) · Health Economics · doi:10.1002/hec.4730030505 · Cited by 963 · see citing works
The logged dependent variable, heteroscedasticity, and the retransformation problem.
Manning, W. (1998) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00025-3 · Cited by 959 · see citing works
Methods for the economic evaluation of health care programmes, 3rd ed
Adamiak, G. T. (2006) · PubMed Central · Cited by 953 · see citing works
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1191/096228099671525676 · Cited by 920 · see citing works
Economic Evaluation in Clinical Trials
Glick, H. A., Doshi, J. A., Sonnad, S. S., & Polsky, D. E. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199685028.001.0001 · Cited by 910 · see citing works
Self-citationApplication of random-effects pattern-mixture models for missing data in longitudinal studies.
Hedeker, D., & Gibbons, R. D. (1997) · Psychological Methods · doi:10.1037/1082-989x.2.1.64 · Cited by 907 · see citing works
Multiattribute Utility Function for a Comprehensive Health Status Classification System
Torrance, G. W., Feeny, D. H., Furlong, W. J., Barr, R. D., ZHANG, Y., & Wang, Q. (1996) · Medical Care · doi:10.1097/00005650-199607000-00004 · Cited by 900 · see citing works
Claxton, K. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00039-3 · Cited by 891 · see citing works
Briggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Medical Decision Making · doi:10.1177/0272989x12458348 · Cited by 887 · see citing works
Self-citationModel Transparency and Validation
Eddy, D. M., Hollingworth, W., Jaime, J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Medical Decision Making · doi:10.1177/0272989x12454579 · Cited by 803 · see citing works
How should cost data in pragmatic randomised trials be analysed?
Thompson, S. G. (2000) · BMJ · doi:10.1136/bmj.320.7243.1197 · Cited by 772 · see citing works
Health status and health policy: quality of life in health care evaluation and resource allocation
(1993) · Choice Reviews Online · doi:10.5860/choice.31-1551 · Cited by 756 · see citing works
Self-Reported Utilization of Health Care Services: Improving Measurement and Accuracy
Bhandari, A., & Wagner, T. H. (2006) · Medical Care Research and Review · doi:10.1177/1077558705285298 · Cited by 732 · see citing works
Ramsey, S. D., Willke, R. J., Briggs, A. H., Brown, R. E., Buxton, M. J., Chawla, A., Cook, J. R., Glick, H. A., Liljas, B., Petitti, D. B., et al. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.00045.x · Cited by 721 · see citing works
Self-citationBriggs, A. H., Weinstein, M. C., Fenwick, E. A. L., Karnon, J., Sculpher, M. J., & Paltiel, A. D. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.014 · Cited by 711 · see citing works
Self-citationConsolidated health economic evaluation reporting standards (CHEERS) statement
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.010 · Cited by 657 · see citing works
Self-citationMultiple Imputation in Practice
Horton, N. J., & Lipsitz, S. R. (2001) · The American Statistician · doi:10.1198/000313001317098266 · Cited by 602 · see citing works
Latimer, N. R. (2013) · Medical Decision Making · doi:10.1177/0272989x12472398 · Cited by 539 · see citing works
Drummond, M., Barbieri, M., Cook, J. R., Glick, H. A., Lis, J., Malik, F., Reed, S., Rutten, F., Sculpher, M. J., & Severens, J. L. (2009) · Value in Health · doi:10.1111/j.1524-4733.2008.00489.x · Cited by 535 · see citing works
Self-citationCoons, S. J., Gwaltney, C. J., Hays, R. D., Lundy, J. J., Sloan, J. A., Revicki, D. A., Lenderking, W. R., Cella, D. F., & Basch, E. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00470.x · Cited by 533 · see citing works
Application of Multi-Attribute Utility Theory to Measure Social Preferences for Health States
Torrance, G. W., Boyle, M. H., & Horwood, S. P. (1982) · Operations Research · doi:10.1287/opre.30.6.1043 · Cited by 522 · see citing works
Mark, D. B., Hlatky, M. A., Califf, R. M., Naylor, C. D., Lee, K. L., Armstrong, P. W., Barbash, G. I., White, H. D., Simoons, M. L., Nelson, C. L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322106 · Cited by 520 · see citing works
Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0168-z · Cited by 517 · see citing works
Richardson, J., Iezzi, A., Khan, M. A., & Maxwell, A. (2014) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-013-0036-x · Cited by 504 · see citing works
The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?
Lauer, M. S., & D'Agostino, R. B. (2013) · New England Journal of Medicine · doi:10.1056/nejmp1310102 · Cited by 497 · see citing works
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.014 · Cited by 495 · see citing works
Panel on cost-effectiveness in health and medicine.
Gold, M. (1996) · PubMed · Cited by 491 · see citing works
Modeling risk using generalized linear models.
Blough, D., Madden, C., & Hornbrook, M. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00032-0 · Cited by 473 · see citing works
A general health policy model: update and applications.
Kaplan, R. M., & Anderson, J. P. (1988) · PubMed · Cited by 472 · see citing works
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.012 · Cited by 466 · see citing works
Estimating Medical Costs from Incomplete Follow-Up Data
Lin, D. Y., Feuer, E. J., Etzioni, R., & Wax, Y. (1997) · Biometrics · doi:10.2307/2533947 · Cited by 455 · see citing works
Accounting for future costs in medical cost-effectiveness analysis
Meltzer, D. O. (1997) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00507-3 · Cited by 447 · see citing works
The death of cost‐minimization analysis?
Briggs, A. H., & OʼBrien, B. J. (2001) · Health Economics · doi:10.1002/hec.584 · Cited by 437 · see citing works
Self-citationStatistics notes: Transformations, means, and confidence intervals: Fig 1
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.312.7038.1079 · Cited by 426 · see citing works
An economic approach to clinical trial design and research priority-setting.
Claxton, K., & Posnett, J. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199611)5:6 · Cited by 416 · see citing works
Whither trial‐based economic evaluation for health care decision making?
Sculpher, M. J., Claxton, K., Drummond, M., & McCabe, C. (2006) · Health Economics · doi:10.1002/hec.1093 · Cited by 408 · see citing works
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, A. H., & Gray, L. J. (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 392 · see citing works
Self-citationRoberts, M. S., Russell, L. B., Paltiel, A. D., Chambers, M. R., McEwan, P. C., & Krahn, M. D. (2012) · Medical Decision Making · doi:10.1177/0272989x12454941 · Cited by 391 · see citing works
The structure of demand for health care: latent class versus two-part models.
Deb, P., & Trivedi, P. (2002) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00008-5 · Cited by 380 · see citing works
Carrier Screening for Cystic Fibrosis
Asch, D. A., Hershey, J. C., DeKay, M. L., Pauly, M. V., Patton, J. P., Jedrziewski, M. K., Frei, F. X., Giardine, R., Kant, J. A., & Mennuti, M. T. (1998) · Medical Decision Making · doi:10.1177/0272989x9801800209 · Cited by 375 · see citing works
Expected Value of Sample Information Calculations in Medical Decision Modeling
Ades, A. E., Lu, G., & Claxton, K. (2004) · Medical Decision Making · doi:10.1177/0272989x04263162 · Cited by 364 · see citing works
Basu, A., & Rathouz, P. (2005) · Biostatistics · doi:10.1093/biostatistics/kxh020 · Cited by 357 · see citing works
Missing.... presumed at random: cost‐analysis of incomplete data
Briggs, A. H., Clark, T. G., Wolstenholme, J. L., & Clarke, P. (2002) · Health Economics · doi:10.1002/hec.766 · Cited by 346 · see citing works
Self-citationModeling Using Discrete Event Simulation
Karnon, J. D., Stahl, J. E., Brennan, A., Jaime, J., Mar, J., & Möller, J. (2012) · Medical Decision Making · doi:10.1177/0272989x12455462 · Cited by 336 · see citing works
Goossens, M. E. J. B., Mölken, M. R., Vlaeyen, J. W. S., & van der Linden, S. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00177-8 · Cited by 335 · see citing works
A Review of Self-Report Instruments Measuring Health-Related Work Productivity
Prasad, M., Wahlqvist, P., Shikiar, R., & Shih, Y. T. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422040-00002 · Cited by 319 · see citing works
Statistics Notes: Transforming data
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.312.7033.770 · Cited by 294 · see citing works
The Distribution of Health Care Costs and Their Statistical Analysis for Economic Evaluation
Briggs, A., & Gray, A. (1998) · Journal of Health Services Research and Policy · doi:10.1177/135581969800300410 · Cited by 288 · see citing works
Self-citationThe black box of health care expenditure growth determinants
Barros, P. P. (1998) · Health Economics · doi:10.1002/(sici)1099-1050(199809)7:6 · Cited by 273 · see citing works
Statistics Notes: The use of transformation when comparing two means
Bland, J. M., & Altman, D. G. (1996) · BMJ · doi:10.1136/bmj.312.7039.1153 · Cited by 270 · see citing works
Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure
Mark, D. B., Nelson, C. L., Anstrom, K. J., Al‐Khatib, S. M., Tsiatis, A. A., Cowper, P. A., Clapp‐Channing, N. E., Davidson-Ray, L. D., Poole, J. E., Johnson, G. W., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.581884 · Cited by 264 · see citing works
The Elgar Companion to Health Economics
(2006) · Edward Elgar Publishing eBooks · doi:10.4337/9781845428914 · Cited by 258 · see citing works
Using a discrete choice experiment to estimate health state utility values
Bansback, N. J., Brazier, J. E., Tsuchiya, A., & Anis, A. H. (2011) · Journal of Health Economics · doi:10.1016/j.jhealeco.2011.11.004 · Cited by 255 · see citing works
Barber, J., & Thompson, S. G. (1998) · BMJ · doi:10.1136/bmj.317.7167.1195 · Cited by 254 · see citing works
Statistics in medical journals: some recent trends
Altman, D. G. (2000) · Statistics in Medicine · doi:10.1002/1097-0258(20001215)19:23 · Cited by 252 · see citing works
Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Roberts, M., Russell, L. B., Paltiel, A. D., Chambers, M., McEwan, P., & Krahn, M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.016 · Cited by 241 · see citing works
Karnon, J., Stahl, J., Brennan, A., Caro, J. J., Mar, J., & Möller, J. (2012) · Value in Health · doi:10.1016/j.jval.2012.04.013 · Cited by 240 · see citing works
Cost Effectiveness of Lung-Volume–Reduction Surgery for Patients with Severe Emphysema
National Emphysema Treatment Trial Research Group (2003) · New England Journal of Medicine · doi:10.1056/nejmsa030448 · Cited by 234 · see citing works
Pitman, R., Fisman, D. N., Zaric, G. S., Postma, M. J., Kretzschmar, M., Edmunds, J., & Brisson, M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.011 · Cited by 223 · see citing works
Belisario, J. S. M., Jamšek, J., Huckvale, K., O’Donoghue, J., Morrison, C. P., & Car, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000042.pub2 · Cited by 216 · see citing works
World development indicators 2001
Other (2001) · Cited by 209 · see citing works
Pearce, J. (1989) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.52.11.1314 · Cited by 203 · see citing works
Nixon, R., Wonderling, D., & Grieve, R. (2010) · Health Economics · doi:10.1002/hec.1477 · Cited by 194 · see citing works
Cook, J., Hislop, J., Adewuyi, T., Harrild, K., Altman, D., Ramsay, C., Fraser, C., Buckley, B., Fayers, P., Harvey, I., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18280 · Cited by 194 · see citing works
Self-citationExpected value of information and decision making in HTA
Eckermann, S. D., & Willan, A. R. (2006) · Health Economics · doi:10.1002/hec.1161 · Cited by 190 · see citing works
The value of information and optimal clinical trial design
Willan, A. R., & Pinto, E. M. (2005) · Statistics in Medicine · doi:10.1002/sim.2069 · Cited by 186 · see citing works
Median Regression with Censored Cost Data
Bang, H., & Tsiatis, A. A. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00643.x · Cited by 185 · see citing works
Alava, M. H., Wailoo, A., & Ara, R. (2012) · Value in Health · doi:10.1016/j.jval.2011.12.014 · Cited by 182 · see citing works
The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data
Desgagné, A., Castilloux, A., Angers, J., & LeLorier, J. (1998) · PharmacoEconomics · doi:10.2165/00019053-199813050-00002 · Cited by 180 · see citing works
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers
Eichler, H., Bloechl‐Daum, B., Abadie, E., Barnett, D. B., König, F., & Pearson, S. D. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3079 · Cited by 174 · see citing works
Design of a National Distributed Health Data Network
Maro, J. C., Platt, R. G., Holmes, J. H., Strom, B. L., Hennessy, S., Lazarus, R. M., & Brown, J. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00139 · Cited by 165 · see citing works
A Note on Confidence Intervals in Cost-Effectiveness Analysis
Tambour, M., Zethraeus, N., & Johannesson, M. (1998) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300011442 · Cited by 156 · see citing works
Mortimer, D., & Segal, L. (2007) · Medical Decision Making · doi:10.1177/0272989x07309642 · Cited by 155 · see citing works
Developing Appropriate Methods for Cost-Effectiveness Analysis of Cluster Randomized Trials
Gomes, M., Ng, E. S. W., Grieve, R., Nixon, R. M., Carpenter, J. R., & Thompson, S. G. (2011) · Medical Decision Making · doi:10.1177/0272989x11418372 · Cited by 153 · see citing works
Assessing the costs of healthcare technologies in clinical trials.
Johnston, K., Buxton, M. J., Jones, & Fitzpatrick, R. M. (1999) · Health Technology Assessment · doi:10.3310/hta3060 · Cited by 148 · see citing works
Valuing SF-6D Health States Using a Discrete Choice Experiment
Norman, R., Viney, R. C., Brazier, J. E., Burgess, L., Cronin, P., King, M. T., Ratcliffe, J., & Street, D. J. (2013) · Medical Decision Making · doi:10.1177/0272989x13503499 · Cited by 143 · see citing works
Patient Self-Reports in Pharmacoeconomic Studies
Evans, C., & Crawford, B. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915030-00004 · Cited by 136 · see citing works
Barbieri, M., Drummond, M., Willke, R. J., Chancellor, J. V. M., Jolain, B., & Towse, A. (2005) · Value in Health · doi:10.1111/j.1524-4733.2005.03070.x · Cited by 129 · see citing works
Self-citationA Comparison of Methods for Analyzing Health-Related Quality-of-Life Measures
Austin, P. C. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.54128.x · Cited by 121 · see citing works
Curtis, L. H., Brown, J. S., & Platt, R. G. (2014) · Health Affairs · doi:10.1377/hlthaff.2014.0121 · Cited by 121 · see citing works
O'Hagan, A., & Stevens, J. W. (2003) · Health Economics · doi:10.1002/hec.699 · Cited by 119 · see citing works
Economic evaluation of pharmaceuticals. Frankenstein's monster or vampire of trials?
O'Brien, B. (1996) · PubMed · Cited by 116 · see citing works
On the use of survival analysis techniques to estimate medical care costs
Etzioni, R., Feuer, E. J., Sullivan, S. D., Lin, D. Y., Hu, C., & Ramsey, S. D. (1999) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00056-3 · Cited by 114 · see citing works
Self-citationIncremental net benefit in randomized clinical trials
Willan, A. R., & Lin, D. Y. (2001) · Statistics in Medicine · doi:10.1002/sim.789 · Cited by 107 · see citing works
Conversion factor instability in international comparisons of health care expenditure
Gerdtham, U., & Jönsson, B. (1991) · Journal of Health Economics · doi:10.1016/0167-6296(91)90005-8 · Cited by 104 · see citing works
Hay, J. W., Smeeding, J., Carroll, N., Drummond, M., Garrison, L. P., Mansley, E. C., Mullins, C. D., Mycka, J., Seal, B., & Shi, L. (2010) · Value in Health · doi:10.1111/j.1524-4733.2009.00663.x · Cited by 103 · see citing works
What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?
Barbieri, M., Drummond, M., Rutten, F., Cook, J. R., Glick, H. A., Lis, J., Reed, S. D., Sculpher, M. J., & Severens, J. L. (2010) · Value in Health · doi:10.1111/j.1524-4733.2010.00771.x · Cited by 101 · see citing works
Self-citationOptimal clinical trial design using value of information methods with imperfect implementation
Willan, A. R., & Eckermann, S. D. (2009) · Health Economics · doi:10.1002/hec.1493 · Cited by 97 · see citing works
Resource costing for multinational neurologic clinical trials: methods and results
Schulman, K. A., Burke, J. E., Drummond, M., Davies, L. M., Carlsson, P., Gruger, J., Harris, A., Lucioni, C., Gisbert, R., Llana, T., et al. (1998) · Health Economics · doi:10.1002/(sici)1099-1050(1998110)7:7 · Cited by 97 · see citing works
Self-citationSchleinitz, M. D., Weiss, J. P., & Owens, D. K. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.01.014 · Cited by 93 · see citing works
COST‐MINIMISATION ANALYSIS VERSUS COST‐EFFECTIVENESS ANALYSIS, REVISITED
Dakin, H., & Wordsworth, S. (2011) · Health Economics · doi:10.1002/hec.1812 · Cited by 92 · see citing works
Ridyard, C. H., & Hughes, D. A. (2012) · Value in Health · doi:10.1016/j.jval.2012.03.004 · Cited by 87 · see citing works
A tale of two (or more) cities: geographic transferability of pharmacoeconomic data.
OʼBrien, B. J. (1997) · PubMed · Cited by 82 · see citing works
Belisario, J. S. M., Huckvale, K., Saje, A., Porcnik, A., Morrison, C. P., & Car, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000042 · Cited by 80 · see citing works
A Bayesian approach to sensitivity analysis
Felli, J. C., & Hazen, G. B. (1999) · Health Economics · doi:10.1002/(sici)1099-1050(199905)8:3 · Cited by 77 · see citing works
Alava, M. H., Wailoo, A., Wolfe, F., & Michaud, K. D. (2013) · Medical Decision Making · doi:10.1177/0272989x13500720 · Cited by 77 · see citing works
Weintraub, W. S., Zhang, Z., Mahoney, E. M., Kolm, P., Spertus, J. A., Jaime, J., Ishak, J., Goldberg, R. J., Tooley, J. F., Willke, R. J., et al. (2005) · Circulation · doi:10.1161/01.cir.0000157146.86758.bc · Cited by 77 · see citing works
Self-citationCraig, B. M., Pickard, A. S., Stolk, E. A., & Brazier, J. E. (2013) · Medical Decision Making · doi:10.1177/0272989x13482524 · Cited by 76 · see citing works
Assessing the appropriateness of combining economic data from multinational clinical trials
Cook, J. R., Drummond, M., Glick, H. A., & Heyse, J. F. (2003) · Statistics in Medicine · doi:10.1002/sim.1389 · Cited by 75 · see citing works
Self-citationBagust, A., & Beale, S. (2013) · Medical Decision Making · doi:10.1177/0272989x13497998 · Cited by 73 · see citing works
Willke, R. J., Zheng, Z., Subedi, P., Althin, R., & Mullins, C. D. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-185 · Cited by 69 · see citing works
Self-citationSpertus, J. A., Tooley, J. F., Jones, P. G., Poston, C., Mahoney, E. M., DEEDWANIA, P. C., Hurley, S., Pitt, B., & Weintraub, W. S. (2002) · American Heart Journal · doi:10.1067/mhj.2002.120775 · Cited by 69 · see citing works
Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma
Sullivan, S. D., Buxton, M. J., Andersson, L. F., Lamm, C. J., Liljas, B., Chen, Y. Z., PAUWELS, R. A., & Weiss, K. B. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.025 · Cited by 69 · see citing works
Self-citationOn estimators of medical costs with censored data
O’Hagan, A., & Stevens, J. (2004) · Journal of Health Economics · doi:10.1016/j.jhealeco.2003.06.006 · Cited by 67 · see citing works
Bayesian Analysis of the Heterogeneity Model
Frühwirth‐Schnatter, S., Tüchler, R., & Otter, T. (2004) · Journal of Business and Economic Statistics · doi:10.1198/073500103288619331 · Cited by 67 · see citing works
Fieller's method and net health benefits
Heitjan, D. F. (2000) · Health Economics · doi:10.1002/1099-1050(200006)9:4 · Cited by 65 · see citing works
Briggs, A. H., Glick, H. A., Lozano‐Ortega, G., Spencer, M., Calverley, P. M. A., Jones, P. W., & Vestbo, J. (2009) · European Respiratory Journal · doi:10.1183/09031936.00153108 · Cited by 65 · see citing works
Self-citationFayers, P. M., & Hays, R. D. (2014) · Value in Health · doi:10.1016/j.jval.2013.12.002 · Cited by 64 · see citing works
A regression-based method for estimating mean treatment cost in the presence of right-censoring
Carides, G. W. (2000) · Biostatistics · doi:10.1093/biostatistics/1.3.299 · Cited by 61 · see citing works
Griffin, S. C., Welton, N. J., & Claxton, K. (2009) · Medical Decision Making · doi:10.1177/0272989x09344746 · Cited by 60 · see citing works
Willan, A. R. (2008) · Clinical Trials · doi:10.1177/1740774508098413 · Cited by 59 · see citing works
Tang, K. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0209-z · Cited by 57 · see citing works
Sample size calculation in economic evaluations
Al, M., van Hout, B. A., Michel, B. C., & Rutten, F. (1998) · Health Economics · doi:10.1002/(sici)1099-1050(199806)7:4 · Cited by 56 · see citing works
Mapping for economic evaluation
Chuang, L., & Whitehead, S. J. (2011) · British Medical Bulletin · doi:10.1093/bmb/ldr049 · Cited by 55 · see citing works
Cost-effectiveness analysis for multinational clinical trials
Pinto, E. M., Willan, A. R., & OʼBrien, B. J. (2005) · Statistics in Medicine · doi:10.1002/sim.2078 · Cited by 53 · see citing works
Analysis of costs and cost-effectiveness in multinational trials
Koopmanschap, M. A., Touw, K. R., & Rutten, F. (2001) · Health Policy · doi:10.1016/s0168-8510(01)00142-7 · Cited by 51 · see citing works
Estimating medical care costs under conditions of censoring
Raikou, M., & McGuire, A. J. (2004) · Journal of Health Economics · doi:10.1016/j.jhealeco.2003.07.002 · Cited by 49 · see citing works
Lee, D. W., Meyer, J. W., & Clouse, J. (2001) · Value in Health · doi:10.1046/j.1524-4733.2001.44012.x · Cited by 48 · see citing works
Berntgen, M., Gourvil, A., Pavlovic, M., Goettsch, W., Eichler, H., & Kristensen, F. B. (2014) · Value in Health · doi:10.1016/j.jval.2014.04.006 · Cited by 47 · see citing works
Carlson, J. J., Thariani, R., Roth, J., Gralow, J. R., Henry, N. L., Esmail, L. C., Deverka, P. A., Ramsey, S. D., Baker, L., & Veenstra, D. L. (2013) · Medical Decision Making · doi:10.1177/0272989x13484388 · Cited by 43 · see citing works
Self-citationBackhouse, M. E., Wonder, M. J., Hornby, E., Kilburg, A., Drummond, M., & Mayer, F. K. (2011) · Value in Health · doi:10.1016/j.jval.2010.11.011 · Cited by 41 · see citing works
Power and Sample Size in Cost- Effectiveness Analysis
LASKA, E. M., Meisner, M., & Siegel, C. (1999) · Medical Decision Making · doi:10.1177/0272989x9901900312 · Cited by 41 · see citing works
Chernyak, N., Ernsting, C., & Icks, A. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-303 · Cited by 40 · see citing works
Wordsworth, S., & Ludbrook, A. (2004) · Health Economics · doi:10.1002/hec.913 · Cited by 40 · see citing works
Estimating a Treatment Effect from Multidimensional Longitudinal Data
Gray, S. M., & Brookmeyer, R. (1998) · Biometrics · doi:10.2307/2533850 · Cited by 37 · see citing works
Economic Evaluation Alongside Multinational Clinical Trials:Study Considerations for GUSTO iib
Jönsson, B., & Weinstein, M. C. (1997) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300010229 · Cited by 36 · see citing works
Choice of test for comparing two groups, with particular application to skewed outcomes
White, I. R., & Thompson, S. G. (2003) · Statistics in Medicine · doi:10.1002/sim.1420 · Cited by 31 · see citing works
Cost effectiveness of antenatal anti-D prophylaxis
Vick, S., Cairns, J., Urbaniak, S. J., Whitfield, C. R., & Raafat, A. (1996) · Health Economics · doi:10.1002/(sici)1099-1050(199607)5:4 · Cited by 30 · see citing works
Chan, K., Willan, A. R., Gupta, M., & Pullenayegum, E. (2014) · Medical Decision Making · doi:10.1177/0272989x13517750 · Cited by 30 · see citing works
Koerkamp, B. G., Spronk, S., Stijnen, T., & Hunink, M. G. M. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00656.x · Cited by 30 · see citing works
Medicare’s DRG-weights in a European environment: the Spanish experience
Cots, F., Elvira, D., Castells, X., & Dalmau, E. (2000) · Health Policy · doi:10.1016/s0168-8510(99)00074-3 · Cited by 29 · see citing works
McTaggart-Cowan, H. M., Teckle, P., & Peacock, S. J. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2013.850420 · Cited by 29 · see citing works
Economic analysis of lung volume reduction surgery as part of the national emphysema treatment trial
Ramsey, S. D., Sullivan, S. D., Kaplan, R. M., Wood, D. E., Chiang, Y.-P., & Wagner, J. L. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)02283-9 · Cited by 28 · see citing works
Self-citationSullivan, S. D., Liljas, B., Buxton, M. J., Lamm, C. J., O’Byrne, P. M., Tan, W. C., & Weiss, K. B. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00137-4 · Cited by 28 · see citing works
Self-citationConverting international cost effectiveness data to UK prices
Gosden, T., & Torgerson, D. J. (2002) · BMJ · doi:10.1136/bmj.325.7358.275 · Cited by 27 · see citing works
Country-specific cost-effectiveness of early intervention with budesonide in mild asthma
Buxton, M. J., Sullivan, S. D., Andersson, L. F., Lamm, C. J., Liljas, B., Busse, W. W., Pedersen, S., & Weiss, K. B. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00108703 · Cited by 27 · see citing works
Self-citationQuentin, W., Rättö, H., Peltola, M., Busse, R., Häkkinen, U., & on behalf of the EuroDRG group (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs482 · Cited by 26 · see citing works
An Analysis of NICEʼs ‘Restricted’ (or ‘Optimized’) Decisions
O'Neill, P. P., & Devlin, N. J. (2010) · PharmacoEconomics · doi:10.2165/11536970-000000000-00000 · Cited by 23 · see citing works
Scuffham, P., Yelland, M. J., Nikles, J., Pietrzak, E. R., & Wilkinson, D. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00218.x · Cited by 23 · see citing works
Principles for planning and conducting comparative effectiveness research
Luce, B. R., Drummond, M., Dubois, R. W., Neumann, P. J., Jönsson, B., Siebert, U., & Schwartz, J. S. (2012) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.12.41 · Cited by 21 · see citing works
Briggs, A. H., & Tambour, M. (2001) · Drug Information Journal · doi:10.1177/009286150103500441 · Cited by 19 · see citing works
Self-citationRelative effectiveness and the European pharmaceutical market
Jönsson, B. (2011) · The European Journal of Health Economics · doi:10.1007/s10198-011-0297-z · Cited by 16 · see citing works
The Road Not Taken: Transferability Issues in Multinational Trials
Vemer, P., & Mölken, M. R. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0084-z · Cited by 8 · see citing works
Estimating Costs for Economic Evaluation
Raikou, M., & McGuire, A. J. (2012) · Edward Elgar Publishing eBooks · doi:10.4337/9780857938138.00060 · Cited by 7 · see citing works
Flagged first, then by citations
1 of the 184 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.11.1351 · Cited by 1,123 · see citing works
Self-citationMichie, S., Yardley, L., West, R., Patrick, K., & Greaves, F. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.7126 · Cited by 865 · see citing works
“However, existing economic approaches (eg, ISPOR guidance [29]) will need to be adapted to take into account the way digital health interventions are delivered, covering the whole life cycle of the intervention.”
BackgroundHusereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Value in Health · doi:10.1016/j.jval.2021.10.008 · Cited by 847 · see citing works
Self-citationHusereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · BMJ · doi:10.1136/bmj-2021-067975 · Cited by 488 · see citing works
Self-citationHusereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02204-0 · Cited by 450 · see citing works
Self-citationHe, J., Irazola, V., Mills, K. T., Poggio, R., Beratarrechea, A., Dolan, J., Chen, C.-S., Gibbons, L., Krousel-Wood, M., Bazzano, L. A., et al. (2017) · JAMA · doi:10.1001/jama.2017.11358 · Cited by 241 · see citing works
Self-citationHusereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462321001732 · Cited by 227 · see citing works
Self-citationMarcus, H. J., Ramirez, P. T., Khan, D. Z., Horsfall, H. L., HANRAHAN, J. G., Williams, S. C., Beard, D. J., Bhat, R. A., Catchpole, K. C., Cook, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02732-7 · Cited by 213 · see citing works
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Applied Health Economics and Health Policy · doi:10.1007/s40258-021-00704-x · Cited by 211 · see citing works
Self-citationIMPROVE Trial Investigators (2017) · BMJ · doi:10.1136/bmj.j4859 · Cited by 163 · see citing works
Wolowacz, S. E., Briggs, A. H., Belozeroff, V., Clarke, P., Doward, L. C., Goeree, R. A., Lloyd, A. J., & Norman, R. (2016) · Value in Health · doi:10.1016/j.jval.2016.06.001 · Cited by 159 · see citing works
Self-citationHusereau, D., Drummond, M., Augustovski, F., Briggs, A., Carswell, C., Caulley, L., Chaiyakunapruk, N., de Bekker‐Grob, E., Greenberg, D., Loder, E., et al. (2022) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.17012 · Cited by 150 · see citing works
Self-citationHusereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · MDM Policy & Practice · doi:10.1177/23814683211061097 · Cited by 149 · see citing works
Self-citationLinear mixed models to handle missing at random data in trial‐based economic evaluations
Gabrio, A., Plumpton, C., Banerjee, S., & Leurent, B. (2022) · Health Economics · doi:10.1002/hec.4510 · Cited by 138 · see citing works
Cost‐effectiveness of emergency department‐initiated treatment for opioid dependence
Busch, S. H., Fiellin, D. A., Chawarski, M. C., Owens, P. H., Pantalon, M. V., Hawk, K. F., Bernstein, S. L., O’Connor, P. G., & D’Onofrio, G. (2017) · Addiction · doi:10.1111/add.13900 · Cited by 128 · see citing works
Screening and Intervention to Prevent Falls and Fractures in Older People
Lamb, S. E., Bruce, J., Hossain, A., Ji, C., Longo, R., Lall, R., Bojke, C., Hulme, C. T., Withers, E. J., Finnegan, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001500 · Cited by 127 · see citing works
Andronis, L., Kinghorn, P., Qiao, S., Whitehurst, D. G. T., Durrell, S., & McLeod, H. (2016) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0268-8 · Cited by 115 · see citing works
“While good practice guidelines for conducting economic evaluations suggest that appraisal of interventions that are likely to affect absenteeism should include productivity costs [53, 54], there was considerable variation amongst studies in relation to the inclusion of such costs.”
BackgroundBlueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 121 · see citing works
Hernández-Tejedor, A., Peñuelas, Ó., Sirgo, G., Llompart-Pou, J. A., Herrejon, E. P., Estella, Á., Cabanes, M. P. F., Alcalá-Llorente, M. A., Galleymore, P. R., Azuara, B. O., et al. (2017) · Medicina Intensiva · doi:10.1016/j.medin.2017.03.004 · Cited by 104 · see citing works
Challenges in synthesising cost-effectiveness estimates
Shields, G., & Elvidge, J. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01536-x · Cited by 101 · see citing works
Use of Checklists in Reviews of Health Economic Evaluations, 2010 to 2018
Watts, R., & Li, I. W. (2018) · Value in Health · doi:10.1016/j.jval.2018.10.006 · Cited by 97 · see citing works
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · PharmacoEconomics · doi:10.1007/s40273-021-01112-8 · Cited by 95 · see citing works
Self-citationInterventions to increase attendance for diabetic retinopathy screening
Lawrenson, J. G., Graham-Rowe, E., Lorencatto, F., Burr, J. M., Bunce, C., Francis, J., Aluko, P., Rice, S. J. C., Vale, L. D., Pető, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012054.pub2 · Cited by 92 · see citing works
Designing and undertaking a health economics study of digital health interventions
McNamee, P., Murray, E., Kelly, M. P., Bojke, L., Chilcott, J., Fischer, A., West, R., & Yardley, L. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.05.007 · Cited by 82 · see citing works
“To enhance the conduct and reporting of trial-based economic evaluation studies applied to new medicines, medical devices, and procedures, the International Society for Pharmacoeconomics and Outcomes Research has published an updated good research practice guide.(1) This re-emphasizes the need to base economic evidenc…”
MethodJahoda, A. J., Hastings, R. P., Hatton, C., Cooper, S., Dagnan, D., Zhang, R., McConnachie, A., McMeekin, N., Appleton, K., Jones, R., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30426-1 · Cited by 87 · see citing works
Self-citationRadford, K., Sutton, C., Sach, T., Holmes, J. A., Watkins, C. L., Forshaw, D., Jones, T. M., Hoffman, K., O’Connor, R. J., Tyerman, R., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22330 · Cited by 83 · see citing works
Mazzei, D. R., Ademola, A., Abbott, J. H., Sajobi, T., Hildebrand, K. A., & Marshall, D. A. (2020) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2020.10.002 · Cited by 83 · see citing works
Steuten, L., Goulart, B. H. L., Meropol, N. J., Pritchard, D. E., & Ramsey, S. D. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00002 · Cited by 78 · see citing works
Self-citationBuntrock, C., Berking, M., Smit, F., Lehr, D., Nobis, S., Riper, H. M., Cuijpers, P. J., & Ebert, D. D. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.6587 · Cited by 78 · see citing works
“We conducted and reported the health-economic evaluation in agreement with the Consolidated Health Economic Evaluation Reporting Standards statement [17] and the guidelines from the International Society for Pharmacoeconomics and Outcomes Research [18].”
Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT
Scarborough, M., Li, H. K., Rombach, I., Zambellas, R., Walker, A. S., McNally, M., Atkins, B. L., Kümin, M., Lipsky, B. A., Hughes, H. C., et al. (2019) · Health Technology Assessment · doi:10.3310/hta23380 · Cited by 77 · see citing works
“5) Details on lower limb infections n = 436 n = 418 n = 854 Hip 110 (25) 104 (25) 214 (25) Knee 133 (31) 115 (27) 248 (29) Foot 89 (20) 86 (21) 175 (20) Other area of lower limb infection 105 (24) 113 (27) 218 (26) Operative findings Draining sinus arising from bone/prosthesis 177 (34) 142 (27) 319 (30) Frank pus adja…”
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.01.011 · Cited by 76 · see citing works
Self-citationImplementing economic evaluation in simulation‐based medical education: challenges and opportunities
Lin, Y., Cheng, A., Hecker, K. G., Grant, V. J., & Currie, G. R. (2017) · Medical Education · doi:10.1111/medu.13411 · Cited by 74 · see citing works
Katz, N. P., Dworkin, R. H., North, R. B., Thomson, S., Eldabe, S. S., Hayek, S. M., Kopell, B. H., Markman, J. D., Rezai, A. R., Taylor, R. S., et al. (2021) · Pain · doi:10.1097/j.pain.0000000000002204 · Cited by 73 · see citing works
Chalmers, J. R., Haines, R., Mitchell, E. J., Thomas, K. S., Brown, S., Ridd, M. J., Lawton, S., Simpson, E. L., Cork, M. J., Sach, T., et al. (2017) · Trials · doi:10.1186/s13063-017-2031-3 · Cited by 73 · see citing works
Petroff, D., Czerny, M., Kölbel, T., Melissano, G., Lönn, L., Haunschild, J., von ASPERN, K., Neuhaus, P., Pelz, J. O., Epstein, D. M., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025488 · Cited by 71 · see citing works
“Bootstrap methods will be used to characterise uncertainty.(26) Further details will be provided in a statistical analysis plan.”
BackgroundMethodThe statistical approach in trial-based economic evaluations matters: get your statistics together!
Mutubuki, E. N., Alili, M. E., Bosmans, J. E., Oosterhuis, T., Snoek, F. J., Ostelo, R., van Tulder, M. W., & van Dongen, J. M. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06513-1 · Cited by 72 · see citing works
Thorn, J. C., Davies, C. F., Brookes, S. T., Noble, S. M., Dritsaki, M., Gray, E., Hughes, D. A., Mihaylova, B., Petrou, S., Ridyard, C., et al. (2021) · Value in Health · doi:10.1016/j.jval.2020.10.002 · Cited by 70 · see citing works
“Prespecified analysis plans have been used in other areas of economics(6); however, guidance on preparing HEAPs for economic evaluations conducted alongside RCTs and their appropriate content is currently sparse.(7) HEAPs are rarely published; the few examples are typically standalone appendices(8) or part of a SAP,(9…”
Home‐based pulmonary rehabilitation for COPD using minimal resources: An economic analysis
Burge, A. T., Holland, A. E., McDonald, C. F., Abramson, M. J., Hill, C. J., Lee, A. L., Cox, N. S., Moore, R., Nicolson, C., O’Halloran, P., et al. (2019) · Respirology · doi:10.1111/resp.13667 · Cited by 68 · see citing works
Rombey, T., Eckhardt, H., Kiselev, J., Silzle, J., Mathes, T., & Quentin, W. (2023) · BMC Medicine · doi:10.1186/s12916-023-02977-6 · Cited by 67 · see citing works
Social Media and Obesity in Adults: a Review of Recent Research and Future Directions
Waring, M. E., Jake‐Schoffman, D. E., Holovatska, M. M., Mejia, C., Williams, J. C., & Pagoto, S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1001-9 · Cited by 67 · see citing works
Hobeika, C., Pfister, M., Geller, D. A., Tsung, A., Chan, A. C. Y., Troisi, R. I., Rela, M., Benedetto, F. D., Sucandy, I., Nagakawa, Y., et al. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006365 · Cited by 66 · see citing works
“The jury considered that pragmatic study designs with formal economic evaluations providing trial-based comparative cost-effectiveness analyses 201,202 should be prioritized in these situations (Table 4).”
Mant, D., Gray, A. M., Pugh, S. A., Campbell, H., George, S., Fuller, A., Shinkins, B., Corkhill, A., Mellor, J., Dixon, E. L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21320 · Cited by 66 · see citing works
Hermans, J., Bierma‐Zeinstra, S., Bos, P. K., Niesten, D. D., Verhaar, J. A. N., & Reijman, M. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2546-8 · Cited by 64 · see citing works
A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women
Khoa, L. D., Vuong, L. N., Ho, T. M., Dang, V. Q., Pham, T. D., Pham, C. T., Norman, R. J., & Mol, B. W. (2018) · Human Reproduction · doi:10.1093/humrep/dey253 · Cited by 62 · see citing works
Kählke, F., Buntrock, C., Smit, F., & Ebert, D. D. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00702-w · Cited by 66 · see citing works
Bosman, M., Weerts, Z. Z. R. M., Snijkers, J. T. W., Vork, L., Mujagic, Z., Masclee, A., Jonkers, D. M. A. E., & Keszthelyi, D. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.017 · Cited by 62 · see citing works
Vestergaard, A. S., Hansen, L., Sørensen, S. S., Jensen, M. B., & Ehlers, L. H. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-031670 · Cited by 60 · see citing works
“19 Thus, a particular strength of this study was the micro-costing approach, including the availability of information on patient-specific resource usage from the Danish registers.”
Yang, F. B., Dawes, P., Leroi, I., & Gannon, B. (2017) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4771 · Cited by 60 · see citing works
Udsen, F. W., Lilholt, P. H., Hejlesen, O. K., & Ehlers, L. H. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014616 · Cited by 60 · see citing works
“Current good practise for trial-based economic evaluation recommends that analyses should account for missing data by imputation, especially when there is a large amount of missing data.(41) The applied imputation procedure followed the principles recommended by Faria et al.”
Cost-Effectiveness of Supplemental Donor Milk Versus Formula for Very Low Birth Weight Infants
Trang, S., Zupancic, J. A. F., Unger, S. L., Kiss, A., Bando, N., Wong, S. E., Gibbins, S., O’Connor, D. L., & on behalf of the GTA DoMINO Feeding Group (2018) · PEDIATRICS · doi:10.1542/peds.2017-0737 · Cited by 60 · see citing works
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · Health Policy OPEN · doi:10.1016/j.hpopen.2021.100063 · Cited by 58 · see citing works
Self-citationAssessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A
Cook, K., Forbes, S. P., Adamski, K. N., Janice, J., Chawla, A., & Garrison, L. P. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1721508 · Cited by 58 · see citing works
Franklin, M. K., & Thorn, J. C. (2019) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0649-9 · Cited by 57 · see citing works
Kool, M., Van, H., Bartak, A., de Maat, S. D., Arntz, A., van den Eshof, J. W., Peen, J., Blankers, M., Bosmans, J., & Dekker, J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1829-1 · Cited by 23 · see citing works
Ebert, D. D., Kählke, F., Buntrock, C., Berking, M., Smit, F., Heber, E., Baumeister, H., Funk, B., Riper, H. M., & Lehr, D. (2017) · Scandinavian Journal of Work Environment & Health · doi:10.5271/sjweh.3691 · Cited by 57 · see citing works
Riis, A., Jensen, C. E., Bro, F., Maindal, H. T., Petersen, K. D., Bendtsen, M. D., & Jensen, M. B. (2016) · Implementation Science · doi:10.1186/s13012-016-0509-0 · Cited by 55 · see citing works
“The evaluation was carried out as a within-trial assessment with a 12-week time horizon [14].”
MethodGeneral population normative data for the EQ-5D-3L in the five largest European economies
Janssen, M. F., Pickard, A. S., & Shaw, J. W. (2021) · The European Journal of Health Economics · doi:10.1007/s10198-021-01326-9 · Cited by 55 · see citing works
Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke
Gao, L., Moodie, M., Mitchell, P. J., Churilov, L. P., Kleinig, T. J., Yassi, N., Yan, B., Parsons, M. W., Donnan, G. A., Davis, S. M., et al. (2020) · Stroke · doi:10.1161/strokeaha.120.029666 · Cited by 55 · see citing works
Deer, T. R., Hayek, S. M., Grider, J. S., Hagedorn, J. M., McDowell, G. C., II, Kim, P., Dupoiron, D., Goel, V., Duarte, R. V., Pilitsis, J. G., et al. (2024) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2024.03.003 · Cited by 54 · see citing works
Pooran, A., Theron, G., Zijenah, L. S., Chanda, D. M., Clowes, P., Mwenge, L., Mutenherwa, F., Leccese, P. A., Metcalfe, J. Z., Sohn, H., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(19)30164-0 · Cited by 54 · see citing works
Nixon, J., Brown, S. T., Smith, I. L., McGinnis, E., Vargas‐Palacios, A., Nelson, E. A., Brown, J. M., Coleman, S. B., Collier, H., Fernandez, C., et al. (2019) · Health Technology Assessment · doi:10.3310/hta23520 · Cited by 53 · see citing works
Xie, Y., Gunasekeran, D. V., Balaskas, K., Keane, P. A., Sim, D. A., Bachmann, L. M., Macrae, C., & Ting, D. S. W. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.2.22 · Cited by 59 · see citing works
Flórez-Tanus, Á., Padilla, D. P., Zakzuk, J., Caraballo, L. R., & Alvis‐Guzmán, N. (2018) · World Allergy Organization Journal · doi:10.1186/s40413-018-0205-4 · Cited by 52 · see citing works
“The International Society of Pharmacoeconomics and Outcomes Research – ISPOR good research practice guidelines were used for cost data analysis [42].”
MethodJensen, C. E., Riis, A., Petersen, K. D., Jensen, M. B., & Pedersen, K. M. (2017) · Pain · doi:10.1097/j.pain.0000000000000851 · Cited by 50 · see citing works
“Furthermore, statistical analyses were conducted on the basis of intention-to-treat and in accordance with current guidelines on conducting economic evaluations alongside clinical trials.(34)”
MethodTomaszewski, K. J., Ferko, N. C., Hollmann, S., Eng, S., Richard, H., Rowe, L., & Sproule, S. (2017) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s121230 · Cited by 51 · see citing works
Giné‐Garriga, M., Coll‐Planas, L., Guerra-Balic, M., Domingo, À., Figuls, M. R. I., Caserotti, P., Denkinger, M. D., Rothenbacher, D., Tully, M. A., Kee, F., et al. (2017) · Trials · doi:10.1186/s13063-017-1956-x · Cited by 50 · see citing works
Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E. W., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., et al. (2022) · BMC Public Health · doi:10.1186/s12889-021-12491-0 · Cited by 50 · see citing works
Self-citationEdwards, K., Jones, N., Newton, J. L., Foster, C. E., Judge, A., Jackson, K., Arden, N., & Pinedo‐Villanueva, R. (2017) · Health Economics Review · doi:10.1186/s13561-017-0173-3 · Cited by 49 · see citing works
The Current Status of EMDR Therapy, Specific Target Areas, and Goals for the Future
Matthijssen, S. J. M. A., Lee, C. W., de Roos, C., Barron, I. G., Jarero, I., Shapiro, E., Hurley, E. C., Schubert, S. J., Baptist, J., Amann, B. L., et al. (2020) · Journal of EMDR Practice and Research · doi:10.1891/emdr-d-20-00039 · Cited by 48 · see citing works
“Future research into the cost-effectiveness of EMDR should be guided by expert guidelines in this area such as CHEERS (Husereau et al., 2013) or the ISPOR Good Research Practices Task Force Report (Ramsey et al., 2015).”
Conducting Trial-Based Economic Evaluations Using R: A Tutorial
Ben, Â. J., van Dongen, J. M., Alili, M. E., Eßer, J., Broulíková, H. M., & Bosmans, J. E. (2023) · PharmacoEconomics · doi:10.1007/s40273-023-01301-7 · Cited by 48 · see citing works
Campins, L., Serra‐Prat, M., Palomera, E., Bolíbar, I., Martínez, M. À., & Gallo, P. (2017) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2017.09.002 · Cited by 47 · see citing works
Mangalore, R. P., Peel, T. N., Udy, A. A., & Peleg, A. Y. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad223 · Cited by 49 · see citing works
Dehmer, S. P., Maciosek, M. V., Trower, N. K., Asche, S. E., Bergdall, A. R., Nyboer, R. A., O’Connor, P. J., Pawloski, P. A., Sperl‐Hillen, J. M., Green, B. B., et al. (2018) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1001 · Cited by 46 · see citing works
Hughes, D. A., Charles, J. M., Dawoud, D., Edwards, R. T., Holmes, E. A. F., Jones, C., Parham, P. E., Plumpton, C., Ridyard, C. H., Lloyd‐Williams, H., et al. (2016) · PharmacoEconomics · doi:10.1007/s40273-015-0371-y · Cited by 45 · see citing works
“Approaches to trial-based economic evaluation have consequently evolved, as detailed in recent guidelines and reviews [2-4].”
König, H., Bleibler, F., Friederich, H., Herpertz, S., Lam, T., Mayr, A. J., Schmidt, F., Svaldi, J., Zipfel, S., Brettschneider, C., et al. (2018) · International Journal of Eating Disorders · doi:10.1002/eat.22822 · Cited by 45 · see citing works
“The recommended perspective for economic evaluations is the societal perspective wherein possibly all kinds of resource use are considered (Ramsey et al., 2015).”
BackgroundLung, T. W.-C., Marks, G. B., Nhung, N. V., Nguyen, T. A., Hoa, N. L. P., Anh, L. T. N., Hoa, N. B., Britton, W. J., Bestrashniy, J., Jan, S., et al. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30520-5 · Cited by 45 · see citing works
van Dongen, J. M., Persoon, S., Jongeneel, G., Bosmans, J. E., Kersten, M. J., Brug, J., Nollet, F., Chinapaw, M. J. M., & Buffart, L. M. (2019) · Journal of Cancer Survivorship · doi:10.1007/s11764-019-00775-9 · Cited by 45 · see citing works
“This is due to differences in the applied statistical methods, including (1) the use of mixed effect models in the effectiveness analyses, which are typically not applied in cost-effectiveness analyses, (2) multiple imputation, which is recommended for imputing missing cost data [26] versus maximum likelihood estimati…”
MethodThe DISCHARGE Trial Group, Napp, A. E., Haase, R., Laule, M., Schuetz, G. M., Rief, M., Dreger, H., Feuchtner, G. M., Friedrich, G. J., Špaček, M., et al. (2016) · European Radiology · doi:10.1007/s00330-016-4620-z · Cited by 43 · see citing works
Schaub, M. P., Blankers, M., Lehr, D., Boß, L., Riper, H. M., Dekker, J., Goudriaan, A. E., Maier, L. J., Haug, S., Amann, M., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011457 · Cited by 43 · see citing works
“Cost-effectiveness calculations The economic evaluation will be conducted alongside the randomised trial, taking into account the CHEERS statement(66) and the 2015 ISPOR good research practices task force report on cost-effectiveness analysis alongside clinical trials.(67) From the technical point of view, the economi…”
MethodOoms, P., Blankers, M., Figee, M., Bergfeld, I. O., van den Munckhof, P., Schuurman, P. R., & Denys, D. A. J. P. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.04.120 · Cited by 43 · see citing works
Dakin, H., & Gray, A. M. (2017) · Statistics in Medicine · doi:10.1002/sim.7322 · Cited by 43 · see citing works
“172); given that most two-arm trials are not powered to detect significant differences in mean costs or NMB [4,62] and the variance around the interaction term is four-fold higher than that for main effects [17,23], this finding is likely to be common among economic evaluations of factorial trials.”
BackgroundMethodInfluentialBatchelor, J., Millington, A., Thomas, K. S., Akram, P., Azad, J., Bewley, A., Chalmers, J. R., Cheung, S. T., Duley, L., Eleftheriadou, V., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24640 · Cited by 43 · see citing works
“Number unblinded, n (%) 45 (39) 66 (55) 55 (44)”
Feliu‐Soler, A., Borràs, X., Peñarrubia‐María, M. T., Rozadilla‐Sacanell, A., D’Amico, F., Moss-Morris, R. E., Howard, M. A., Fayed, N. M., Soriano‐Mas, C., Puebla‐Guedea, M., et al. (2016) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1068-2 · Cited by 42 · see citing works
“Gotink RA, Chu P, Busschbach JJ, Benson H, Fricchione GL, Hunink MG. Standardised mindfulness-based interventions in healthcare: an overview of systematic reviews and meta-analyses of RCTs. PLoS ONE.”
MethodInfluentialThomas, K. S., Bradshaw, L. E., Sach, T., Cowdell, F., Batchelor, J., Lawton, S., Harrison, E., Haines, R., Ahmed, A. I., Dean, T., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21160 · Cited by 43 · see citing works
“ICERs will be calculated using accepted methodology (Ramsey et al 2015, Drummond et al 2005).”
MethodFor the EVINCI Investigators, Lorenzoni, V., Bellelli, S., Caselli, C., Knuuti, J. M., Underwood, S. R., Neglia, D., & Turchetti, G. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01096-5 · Cited by 42 · see citing works
Alili, M. E., van Dongen, J. M., Eßer, J., Heymans, M. W., van Tulder, M. W., & Bosmans, J. E. (2022) · Health Economics · doi:10.1002/hec.4603 · Cited by 41 · see citing works
“Over the last decades, various recommendations have been made on how to analyze trial-based economic evaluations (Petrou & Gray, 2011; Ramsey et al., 2015; van Dongen et al., 2014).”
BackgroundMethodCost-effectiveness of home-based cardiac rehabilitation: a systematic review
Shields, G., Rowlandson, A., Dalal, G., Nickerson, S., Cranmer, H., Capobianco, L., & Doherty, P. (2023) · Heart · doi:10.1136/heartjnl-2021-320459 · Cited by 41 · see citing works
Luciano, J. V., D'Amico, F., Feliu-Soler, A., McCracken, L. M., Aguado, J., Peñarrubia-María, M. T., Knapp, M., Serrano-Blanco, A., & García-Campayo, J. (2017) · The Journal of Pain · doi:10.1016/j.jpain.2017.03.001 · Cited by 42 · see citing works
Kunst, N., Siu, A., Drummond, M., Grimm, S. E., Grutters, J. P. C., Husereau, D., Koffijberg, H., Rothery, C., Wilson, E., & Heath, A. (2023) · Value in Health · doi:10.1016/j.jval.2023.06.014 · Cited by 40 · see citing works
Berdahl, J. P., Khatana, A. K., Katz, L. J., Herndon, L. W., Layton, A. J., Yu, T. M., Bauer, M. J., & Cantor, L. B. (2017) · Journal of Medical Economics · doi:10.1080/13696998.2017.1327439 · Cited by 40 · see citing works
Gyamfi‐Bannerman, C., Zupancic, J. A. F., Sandoval, G. J., Grobman, W. A., Blackwell, S. C., Tita, A., Reddy, U. M., Jain, L., Saade, G. R., Rouse, D. J., et al. (2019) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2019.0032 · Cited by 39 · see citing works
Cost-effectiveness of adherence-enhancing interventions: a systematic review
Simon‐Tuval, T., Neumann, P. J., & Greenberg, D. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2016.1138858 · Cited by 38 · see citing works
“An ideal comparator is one that represents the best current or most common practice (ideally both).[66] The most common practice does not include any educational communication, thus it was reasonable to choose usual care as a comparator and conclude that these counseling strategies are cost-effective; however, it may…”
BackgroundHernández-Tejedor, A., Peñuelas, Ó., Sirgo, G., Llompart-Pou, J. A., Herrejon, E. P., Estella, Á., Cabanes, M. P. F., Alcalá-Llorente, M. A., Galleymore, P. R., Azuara, B. O., et al. (2017) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2017.03.008 · Cited by 37 · see citing works
Paniagua-Ávila, A., Fort, M. P., Glasgow, R. E., Gulayin, P., Hernández-Galdamez, D. R., Mansilla, K., Palacios, E., Peralta-García, A., Roche, D., Rubinstein, A., et al. (2020) · Trials · doi:10.1186/s13063-020-04345-8 · Cited by 38 · see citing works
“We will analyze differences in costs following a similar analytical approach as that used for estimating health outcomes [32].”
MethodSathish, T., Oldenburg, B. F., Thankappan, K. R., Absetz, P., Shaw, J. E., Tapp, R. J., Zimmet, P., Balachandran, S., Shetty, S. S., Aziz, Z., et al. (2020) · BMC Medicine · doi:10.1186/s12916-020-01704-9 · Cited by 38 · see citing works
“We estimated costs from the health system and societal perspectives, in accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [23] and cost-effectiveness analysis guidelines [24, 25].”
BackgroundMethodInfluentialAlshamsi, S., Hamidi, S., & Narcı, H. Ö. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07663-6 · Cited by 38 · see citing works
A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis
Flight, L., Arshad, F., Barnsley, R., Patel, K., Julious, S. A., Brennan, A., & Todd, S. (2019) · Value in Health · doi:10.1016/j.jval.2018.11.008 · Cited by 36 · see citing works
Gomez-Rossi, J., Feldberg, B., Krois, J., & Schwendicke, F. (2022) · JMIR Medical Informatics · doi:10.2196/33703 · Cited by 39 · see citing works
Hurley, D. A., Hall, A. M., Murphy, L., Pincus, T., Kamper, S. J., Maher, C. G., McDonough, S., Lonsdale, C., Walsh, N. E., Guérin, S., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010728 · Cited by 37 · see citing works
“Finally, the cost of the SOLAS intervention compared with usual PT will be calculated from the health service and societal perspectives using data from resource utilisation measures, alongside exploratory analysis of quality-adjusted life years (EQ-5D) and disease-specific measures.(85)”
MethodAugustovski, F., Chaparro, M., Palacios, A., Shi, L., Beratarrechea, A. G., Irazola, V. E., Rubinstein, A., Mills, K. T., He, J., & Pichón-Rivière, A. (2018) · Value in Health · doi:10.1016/j.jval.2018.06.003 · Cited by 37 · see citing works
“Analyses were conducted following state-of-the-art methods of trial-based economic evaluation.(11) The Institutional Review Boards of Tulane University in the US and Hospital Italiano de Buenos Aires in Argentina approved the study protocol with the planned economic evaluation.”
BackgroundMethodSelf-citation
- Authors
- Ramsey, S. D., Willke, R. J., Glick, H., Reed, S. D., Augustovski, F., Jonsson, B., Briggs, A., & Sullivan, S. D.
- Affiliations
- University of Washington (US)
- Pfizer (United States) (US)
- University of Pennsylvania (US)
- Duke University (US)
- Universidad de Buenos Aires (AR)
- University of Glasgow (GB)
- Corresponding author
- Ramsey, Scott D.
- ORCID
- Venue
- Value in Health
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 18
- Issue
- 2
- Pages
- 161-172
- ISSN
- 1098-3015 (ISSN-L)
- OpenAlex
- W2139814250
- Cited by
- 811
- References
- 184
- Citations by year
- 2026: 58 · 2025: 75 · 2024: 90 · 2023: 80 · 2022: 100 · 2021: 103 · 2020: 88 · 2019: 65 · 2018: 50 · 2017: 57 · 2016: 37 · 2015: 6
- FWCI
- 17.59
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Value in Health (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- cost-effectiveness analysis, clinical trials, economic evaluation, trial design, health care utilization, health utility, intention-to-treat analysis, subgroup analysis, uncertainty characterization, reporting guidelines, reimbursement decisions, healthcare resource allocation
- MeSH terms
- Cost-Benefit Analysis, Health Policy, Health Services Research, Humans, Randomized Controlled Trials as Topic, Advisory Committees, Research Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
